丨证券研究报告丨 行业研究丨行业周报丨煤炭与消费用燃料 [Table_Title] 供给收缩预期升温，布局正当时 报告要点 [Table_Summary] 如何看待后续煤价走势和 2026 年煤炭配置机会？我们认为，本轮煤炭行情的驱动因素主要来 自供给收缩预期升温、寒潮需求支撑与中长期高股息配置价值的共振，煤价反弹仍有空间。不 过，后续仍需关注政策落实情况以及其他地区核减产能是否跟进。整体来看，尽管 2026 年煤 价改善之路或并非一帆风顺，但我们认为，考虑到 2026 年煤炭需求改善可期、反内卷大背景 下存量供给产能利用率依旧受限，供需改善下煤价中枢仍有望提升。岁末年初险资有望增配煤 炭板块，当前时点建议继续重视煤炭红利配置机会。 分析师及联系人 [Table_Author] 肖勇 赵超 叶如祯 庄越 韦思宇 SAC：S0490516080003 SAC：S0490519030001 SAC：S0490517070008 SAC：S0490522090003 SAC：S0490524120007 SFC：BUT918 SFC：BUY139 请阅读最后评级说明和重要声明 %% %% %% %% researc ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [8] Core Viewpoints - The company's controlled nuclear power generation capacity is expected to achieve a total output of 200.8 billion kWh in 2025, representing a year-on-year increase of 9.66%. However, factors such as declining market transaction prices in some provinces and increased taxes for certain nuclear companies may limit the growth of the nuclear power sector's performance [5][12] - The continuous expansion of renewable energy installations is projected to drive a 31.29% year-on-year increase in renewable energy generation to 43.6 billion kWh by 2025. However, this expansion also leads to significant increases in depreciation and other costs, and the weak pricing of renewable energy, along with a reduced stake in China Nuclear Huineng after capital increase, is expected to continue to pressure the performance contribution from the renewable energy sector [12][12] - Overall, while both nuclear and renewable energy sectors show good performance in terms of generation, the company's annual performance outlook remains stable due to the impacts of electricity prices and taxes [12] Summary by Relevant Sections Event Description - As of December 31, 2025, the company's cumulative operational generation for the year is 244.43 billion kWh, a year-on-year increase of 12.98%. The target for 2026 is set at 259.2 billion kWh, with nuclear power planned at 210 billion kWh and renewable energy at 49.2 billion kWh [5] Event Commentary - In the fourth quarter, the controlled nuclear power generation reached 49.799 billion kWh, a year-on-year increase of 4.88%. The growth rate slowed due to maintenance schedules. Excluding the contribution from the newly commissioned Zhangzhou Unit 1, the fourth-quarter nuclear generation saw a slight decline of 0.41% year-on-year. The overall nuclear generation for 2025 is 200.807 billion kWh, achieving a 9.66% increase and meeting the annual generation plan [12] - The company has a strong reserve of nuclear projects, with 18 units under construction or approved, totaling 20.647 million kW, ensuring substantial growth potential in the long term [12] - The earnings forecast for the company has been adjusted, with expected EPS for 2025-2027 at 0.44 yuan, 0.42 yuan, and 0.48 yuan, corresponding to PE ratios of 20.42x, 21.31x, and 18.75x respectively, maintaining a "Buy" rating [12]

世界经济与海外市场丨点评报告 [Table_Title] 就业稳定，降息暂缓 ——12 月美国非农就业数据点评 丨证券研究报告丨 [Table_Summary] 2025 年 12 月美国劳动力市场数据表现分化：新增非农就业人数小幅低预期，失业率也回落至 政府关门前水平，核心服务通胀可控。总的来看，就业慢降温仍是当前美国就业市场的主线， 并不构成美联储需要尽快降息的原因。往前看，1）就业疲软暂无加速迹象，为美联储决策留下 充足空间，我们维持此前对于美联储 2026 年一季度暂缓降息的判断；2）2026 年 5 月美联储 主席换届，特朗普大概率提名鸽派候选人就任，后视经济情况择机再度开启降息可能性较大， 年内预计累计降息至少 50BP。 报告要点 1 [Table_Title 就业稳定，降息暂缓 2] ——12 月美国非农就业数据点评 分析师及联系人 [Table_Author] 于博 敬成宇 SAC：S0490520090001 SFC：BUX667 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com [Table_Summary2] 事件描述 2026 年 1 月 9 ...

Investment Rating - The report maintains a "Positive" investment rating for the environmental protection industry [13]. Core Insights - The central government has set a target for 2026 to actively resolve local government debt risks, with a focus on replacing hidden debts amounting to 2 trillion yuan in 2025, which has been exceeded by 106.6% [2][6][19]. - The environmental protection sector is expected to benefit significantly from the debt replacement policies, improving cash flow and performance for various companies within the industry [7][23]. - The report highlights that several environmental companies have seen a notable improvement in their accounts receivable, indicating a positive trend in cash flow [9][40]. Summary by Sections Policy and Progress - The National People's Congress approved a resolution to increase local government debt limits for replacing hidden debts, with a structured approach of 6 trillion, 4 trillion, and 2 trillion yuan [6][19]. - As of September 2025, the issuance of special refinancing bonds reached 2.31 trillion yuan, with 2.13 trillion yuan specifically allocated for replacing hidden debts, indicating proactive measures by local governments to address existing debt issues [8][27]. Improvement in Accounts Receivable - Companies like Hanlan Environment and Chuangye Environmental have reported significant recoveries in accounts receivable, with Hanlan recovering approximately 1.53 billion yuan in the first three quarters of 2025 [9][39]. - The overall cash flow for the environmental sector has improved, with a year-on-year increase of 31% in operating cash flow net [9][41]. Investment Logic - The report suggests two investment strategies: focusing on sectors with large accounts receivable and low risk, such as waste incineration and water operations, and identifying leading companies in sectors with high government-related receivables [10][44]. - The report emphasizes the potential for cash flow improvement in the environmental sector due to the ongoing debt replacement policies, which are expected to enhance the repayment capabilities of local governments [42][44].

Core Insights - The report predicts an upcoming adjustment to the Hong Kong Stock Connect list in March 2026, with the announcement expected on February 20, 2026, and implementation on March 6, 2026 [1][6]. Group 1: Event Description - The adjustment period for the Hang Seng Composite Index ended on December 31, 2025, and the new list of stocks for the Hong Kong Stock Connect will be released shortly [6][7]. Group 2: Potential Stocks for Inclusion - A total of 47 stocks are expected to meet the criteria for inclusion in the Hong Kong Stock Connect. The pharmaceutical and biotechnology sector has a significant representation among these potential stocks, including names such as: - **Pharmaceutical and Biotechnology**: 英矽智能, 中慧生物-B, 宝济药业-B, 派格生物医药-B, 劲方医药-B, 轩竹生物-B, 康臣药业, 科济药业-B, 海西新药, 长风药业, 维立志博-B, 林清轩, 歌礼制药-B [7]. - **Software Services**: 经纬天地, 希迪智驾, 卓越睿新, 诺比侃, 赤子城科技, 量化派, 迅策, 聚水潭, 果下科技, 五一视界, HASHKEY HLDGS, 卧安机器人, 滴普科技 [7]. - **Non-Bank Financials**: OSL Group, 耀才证券金融, 轻松健康, 国富量子 [7]. - Other sectors include metals, hardware, banking, automotive, consumer retail, household goods, appliances, machinery, defense, industrial trade, utilities, and medical devices [7]. Group 3: Performance Expectations - Stocks that are about to be included in the Hong Kong Stock Connect are expected to perform strongly. Historical backtesting shows that stocks included in the Connect tend to exhibit significant excess returns before and after their inclusion, particularly with the anticipated continued inflow of southbound capital [8].

- The report does not contain any quantitative models or factors for analysis[1][2][3]

Group 1: Economic Indicators - December CPI increased by 0.8% year-on-year and 0.2% month-on-month, aligning with market expectations[6] - December PPI decreased by 1.9% year-on-year but increased by 0.2% month-on-month, exceeding market expectations of -2.0%[10] - Core CPI remained above 1% for four consecutive months, with a year-on-year increase of 1.2% in December[10] Group 2: Influencing Factors - Seasonal factors and rising gold prices supported the improvement in CPI, particularly in food and beverage categories[10] - The narrowing decline in PPI is attributed to lower year-on-year bases and seasonal price increases during winter[10] - The increase in international non-ferrous metal prices contributed to the month-on-month improvement in PPI[10] Group 3: Future Outlook - CPI is expected to continue fluctuating upwards in early 2026 due to seasonal effects and rising gold prices[10] - PPI may also see a rebound influenced by low base effects and ongoing structural changes in the economy[10] - Economic growth pressures are anticipated in Q1 2026, with a focus on potential monetary easing and fiscal stimulus measures[10] Group 4: Risks - Risks include weaker-than-expected consumer recovery, escalating geopolitical conflicts, and uncertainties surrounding tariff policies[8]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - On December 30, the company plans to acquire a 51% stake in Wenkou Salt Lake from its controlling shareholder, China Salt Lake Group, for approximately 4.605 billion yuan. After the acquisition, Wenkou Salt Lake will become a subsidiary of the company, consolidating its financials [2][4]. - The acquisition is part of a strategic plan by China Salt Lake Group to optimize and integrate resources, aiming to establish a world-class salt lake industry group by 2030 [10]. - The resource integration is expected to enhance the company's lithium and potassium production capacity significantly, with lithium rights capacity increasing to nearly 70,000 tons LCE and potassium fertilizer capacity rising to approximately 5.15 million tons [10]. - The company has a strong cost advantage in lithium and potassium production, with lithium production costs around 40,000-45,000 yuan per ton LCE and potassium fertilizer costs between 1,200-1,500 yuan per ton, positioning it favorably in the global cost curve [10]. - The company is projected to achieve net profits of 668 million yuan, 692 million yuan, and 745 million yuan from 2026 to 2028, supported by rising lithium and potassium prices [10]. Financial Summary - The company's total revenue is expected to grow from 15.134 billion yuan in 2024 to 27.389 billion yuan in 2027, with a corresponding increase in net profit from 4.914 billion yuan to 12.869 billion yuan during the same period [17]. - The earnings per share (EPS) is projected to rise from 0.88 yuan in 2024 to 2.28 yuan in 2027, indicating strong growth potential [17]. - The company's price-to-earnings (PE) ratio is estimated to decrease from 18.68 in 2024 to 12.35 in 2027, suggesting an attractive valuation as earnings grow [17].

Investment Rating - The industry investment rating is "Positive" and maintained [10] Core Insights - The financing ecosystem for China's biopharmaceutical industry is gradually entering a positive cycle, driven by abundant funds from A/H listings and capital increases of innovative drug companies. This is expected to improve the willingness to invest in R&D, leading to a new cycle of prosperity in the innovative drug industry [2][8][57]. Summary by Relevant Sections 2025 Prospective Indicator Trends - In December 2025, the IPO fundraising for pharmaceutical companies in Hong Kong reached 6.2 billion yuan, marking the second-highest monthly level since 2022. The A-share IPO fundraising for unprofitable companies opened up, with amounts of 4.2 billion and 2 billion yuan in October and December respectively [6][32]. - The fundraising scale for A-share pharmaceutical companies in December 2025 was 1.2 billion yuan, showing significant improvement year-on-year. The fundraising scale for Hong Kong pharmaceutical companies reached 13.9 billion HKD, the second-highest monthly level since 2022 [35]. - The total financing amount for China's biopharmaceutical sector in December 2025 was 1.23 billion USD, a new monthly high since 2022 [37]. - The upfront payment for external business development (BD) in Q4 2025 was 2.27 billion USD, with a record high of 1.5 billion USD in October [6][43]. 2025 Indicator Trends Summary - The total IPO fundraising for pharmaceutical companies in A-shares was 9.1 billion yuan in 2025, a year-on-year increase of 216.6%, while H-share IPO fundraising reached 33.6 billion yuan, up 334.7% [46]. - The fundraising scale for A-share pharmaceutical companies was 9.9 billion yuan, a year-on-year increase of 111.1%, and for H-share companies, it was 66.8 billion HKD, up 194.9% [54]. - The number of biopharmaceutical financing projects in China reached 201 in 2025, a year-on-year increase of 18.9%, with total financing amounting to 5.8 billion USD, up 28.0% [54]. - The upfront payment for external BD in 2025 was 6.9 billion USD, a year-on-year increase of 224.9%, with milestone payments reaching 125.98 billion USD, up 185.9% [54]. Overall Summary - The total amount of IPO fundraising, company capital increases, biopharmaceutical financing, and confirmed upfront payments for external BD in 2025 reached 201.5 billion yuan, a year-on-year increase of 145%. The funding levels for innovative drug companies significantly improved compared to 2024. Additionally, potential milestones for external BD reached 880.5 billion yuan, a year-on-year increase of 185.9% [8][50].

Investment Rating - The report maintains a "Buy" rating for the company [9] Core Insights - The company is positioned as a leading platform for marine power systems in China, benefiting from the recovery of the shipbuilding industry and the transition towards clean energy vessels, which is expected to enhance profitability [3][7] - The removal of the 301 policy pressure is anticipated to lead to a significant increase in global shipbuilding orders, with a notable 79% year-on-year increase in December orders [6][21] - The company has been expanding its engine production capacity, with expectations for continued growth in the delivery of low-speed engines and an increase in the proportion of dual-fuel engines, which will further boost profitability [8][72] Summary by Relevant Sections Shipbuilding Industry - The shipbuilding sector is expected to experience an upward turning point as the pressure from the 301 policy is lifted, with a significant increase in new orders and ship prices anticipated [6][17] - The global shipbuilding new orders for 2025 are projected to decline by 24.2% year-on-year, but the removal of the 301 policy is expected to lead to a recovery in orders, particularly for oil tankers, which saw a 284.5% year-on-year increase in November [6][25] - Long-term trends indicate a high proportion of aging vessels, creating substantial demand for vessel replacements and upgrades, driven by stricter environmental regulations [33][37] Company Overview - The company, backed by China Shipbuilding Group, has a significant market share in marine engine orders and is expected to benefit from the ongoing recovery in the shipbuilding sector [7][56] - The company's revenue has been consistently growing, with the diesel power business contributing significantly to its performance, and the gross profit margin for diesel power products has been increasing [58][63] - The company is also focusing on expanding its dual-fuel engine offerings, which are becoming a crucial revenue source as the industry shifts towards cleaner energy solutions [75]